WESTBURY, N.Y., Oct. 31,
2013 /PRNewswire/ -- Vasomedical, Inc. ("Vasomedical") (OTC
BB: VASO), a diversified medical technology company specializing in
the design, manufacture and sale of medical devices for noninvasive
cardiology including EECP® Therapy systems, the gold
standard of ECP therapy, announced today that the Company will
attend the American Heart Association's 2013 Scientific Sessions
from November 16 – 20, 2013 in
Dallas, Texas to exhibit its EECP
Therapy and BIOX™ ambulatory monitoring products.
Additionally, during the Scientific Sessions, Vasomedical has
teamed up with Endothelix Inc. and Ischemic Conditioning
Therapeutics, Inc., both based in Houston, Texas, to co-sponsor an educational
symposium focusing on the state of the art science and technology
related to Endothelial Dysfunction, Enhanced External
Counterpulsation (EECP), Ischemic Conditioning (ICT), and their
potential interactions. This invitation-only scientific
focus group event will take place on Sunday evening, November 17, 2013 from 7:00pm to 9:00pm at the Aloft Hotel in
Dallas. Attendees interested in accepting the invitation
should reserve their seats on the Endothelix website.
The American Heart Association's annual Scientific
Sessions is one of the leading cardiovascular meetings for
basic, translational, clinical and population science in the United
States. Each year, more than 18,000 cardiovascular experts,
from over 105 countries and approximately 1.5 million virtual
professionals attend the Sessions. The event includes five
days of education through more than 5,000 presentations with 1,000
invited faculty and 4,000 abstract presentations from the world's
leaders in cardiovascular disease. More than 200 companies will
exhibit and showcase the latest cardiovascular technology and
products.
"This AHA's Scientific Sessions is one of the biggest events in
cardiology in the United States.
Each year, we look forward to meeting with attendees and exchanging
ideas about expanding EECP Therapy's role in cardiovascular disease
treatment and extolling its significant benefits to patients,
providers and the healthcare system," said Larry Liebman, Vice President of Sales and
Marketing at Vasomedical. "We are pleased to be co-sponsoring the
educational event and to have an opportunity to contribute to a
greater understanding of the importance in preserving and improving
endothelial function to treat and prevent cardiovascular
disease."
Vasomedical will be located in Booth #1439.
About Vasomedical
Vasomedical, Inc. is a diversified
medical technology company specializing in the manufacture and sale
of medical devices and in the domestic sale of diagnostic imaging
products. The Company's main proprietary products are
EECP® Therapy systems, the gold standard of ECP
treatment. The Company operates through three wholly owned
subsidiaries: VasoSolutions, Vasomedical Global and VasoHealthcare.
VasoSolutions manages and coordinates the design, manufacture and
sales of EECP® Therapy systems, and other medical equipment
operations; Vasomedical Global operates the Company's China-based subsidiaries; and VasoHealthcare
is the operating subsidiary for the exclusive sales representation
of GE Healthcare diagnostic imaging products in certain market
segments. Additional information is available on the Company's
website at www.vasomedical.com.
About Biox Instruments
Biox Instruments Co., Ltd., a wholly owned subsidiary of
Vasomedical, is based in Wuxi, Jiangsu
Province, China.
With long established expertise in miniaturization and
low power consumption medical devices, it is a leading
company in ambulatory monitoring systems consisting of ECG Holter
recorders, ambulatory blood pressure monitoring (ABPM) systems as
well as related analysis and reporting software. Biox is in full
compliance of revered quality and manufacturing standards such as
ISO 13485, ISO 9001, US FDA cGMP as well as the Medical Device
Directive of the European Union. Biox products are FDA Cleared, CE
Marked and Health Canada Listed. Furthermore, Biox continues to
provide OEM and OED services to many businesses that require
effective solutions to product design and performance. Additional
information is available on the Company's website
at www.biox.com.cn.
Except for historical information contained in this release,
the matters discussed are forward-looking statements that involve
risks and uncertainties. When used in this release, words such as
"anticipates", "believes", "could", "estimates", "expects", "may",
"plans", "potential" and "intends" and similar expressions, as they
relate to the Company or its management, identify forward-looking
statements. Such forward-looking statements are based on the
beliefs of the Company's management, as well as assumptions made by
and information currently available to the Company's management.
Among the factors that could cause actual results to differ
materially are the following: the effect of business and economic
conditions; the effect of the dramatic changes taking place in the
healthcare environment; the impact of competitive procedures and
products and their pricing; medical insurance reimbursement
policies; unexpected manufacturing or supplier problems; unforeseen
difficulties and delays in the conduct of clinical trials and other
product development programs; the actions of regulatory authorities
and third-party payers in the United
States and overseas; uncertainties about the acceptance of a
novel therapeutic modality by the medical community; continuation
of the GEHC agreement; and the risk factors reported from time to
time in the Company's SEC reports. The Company undertakes no
obligation to update forward-looking statements as a result of
future events or developments.
Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
212-896-1215 / 212-896-1250
tfromer@kcsa.com / grussell@kcsa.com
Media Contacts:
Samantha Wolf / Andrew Herweg
KCSA Strategic Communications
212-896-1220 / 212-896-1273
swolf@kcsa.com / aherweg@kcsa.com
SOURCE Vasomedical, Inc.